Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$153.49 USD

153.49
4,164,591

+3.73 (2.49%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

LabCorp (LH) Tops on Q2 Earnings & Revenues, Narrows '18 View

LabCorp's (LH) Covance Drug Development business has reported sturdy growth on strategic acquisitions, robust organic growth and a positive foreign currency translation.

    Swarup Gupta headshot

    Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions

    Biotech stocks are largely resilient to trade related disruptions.

      AstraZeneca Sells Atacand's European Rights to Cheplapharm

      AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.

        Allergan's Depression Candidate Gets Fast Track Designation

        The FDA grants fast track designation to Allergan's (AGN) AGN-241751, developed for the treatment of patients with major depressive disorder.

          Can Solid Overall Growth Drive Illumina's (ILMN) Q2 Earnings?

          Illumina (ILMN) to gain from strong revenues at the Product, Service and other segments in Q2.

            Tirthankar Chakraborty headshot

            Invest in 5 Mega Trends to Overcome Trade War Jitters

            Companies involved in artificial intelligence, e-commerce, mobile payments, biotechnology and gaming are unperturbed by escalated trade war tensions. We share a few solid stocks from such spaces so that you can trade them.

              Karyopharm Initiates NDA Submission Process for Selinexor

              Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.

                J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

                The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

                  Roche's Tecentriq Gets Breakthrough Therapy Status for HCC

                  The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.

                    J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

                    A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

                      J&J's (JNJ) Phase III Study for Invokana Halted Earlier

                      Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.

                        J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)

                        A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

                          Zacks.com featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina

                          Zacks.com featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina

                            Tirthankar Chakraborty headshot

                            4 Best Efficient Stocks to Add to Your Portfolio

                            A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

                              Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

                              Is (ILMN) Outperforming Other Medical Stocks This Year?

                                BioTime (BTX) in Focus: Stock Moves 7.3% Higher

                                BioTime (BTX) was a big mover last session, as the company saw its shares rise more than 7% on the day.

                                  Why Aptose Biosciences (APTO) Could Be Positioned for a Slump

                                  Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

                                    Zacks Industry Outlook Highlights: Amgen, ANI and Illumina

                                    Zacks Industry Outlook Highlights: Amgen, ANI and Illumina

                                      Biotech Stock Outlook: Short-Term Pricing Pain to Prevail

                                      Decline in sales of high-profile drugs, pipeline setbacks and competitive pressure are likely to adversely impact the overall performance of the biotech sector in the short term.

                                        Alkermes' Aristada Initio Approved by FDA for Schizophrenia

                                        FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.

                                          Roche's Breast Cancer Study Meets Co-Primary Endpoint

                                          Phase III IMpassion130 study shows that Roche???s (RHHBY) Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

                                            Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

                                            Sector ETF report for ARKG

                                              AMGN or ILMN: Which Is the Better Value Stock Right Now?

                                              AMGN vs. ILMN: Which Stock Is the Better Value Option?

                                                Nabaparna Bhattacharya headshot

                                                Genomics Market Gains Momentum: 3 DNA Stocks in Focus

                                                Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.

                                                  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

                                                  Is Illumina, Inc. (ILMN) Outperforming Other Medical Stocks This Year?